Clinical trial
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia…
NCT00482430 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00482430 |
|---|---|
| Title | MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027) |
| Official title | A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Clinical Trial to Study the Safety and Efficacy of MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Paranoid Schizophrenia, Schizophrenia |
| Intervention type | Drug |
| Interventions | MK0557, Comparator: Placebo (unspecified) |
| Enrollment | 50 |
| Start date | Sep 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jun 5, 2007 |
| Last update posted | Aug 21, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: